Literature DB >> 7837762

Effect of betaine on S-adenosylmethionine levels in the cerebrospinal fluid in a patient with methylenetetrahydrofolate reductase deficiency and peripheral neuropathy.

T Kishi1, I Kawamura, Y Harada, T Eguchi, N Sakura, K Ueda, K Narisawa, D S Rosenblatt.   

Abstract

A 16-year-old Japanese girl with 5,10-methylenetetrahydrofolate reductase deficiency showed peripheral neuropathy. There were no significant responses to vitamin B6, vitamin B12 or folate, given alone or in combination. With the addition of betaine monohydrate, she has been free from gait disturbance and muscle weakness. The concentration of S-adenosylmethionine in cerebrospinal fluid, which was undetectable before receiving betaine monohydrate, increased to about the normal level 24 months after treatment with betaine monohydrate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7837762     DOI: 10.1007/bf00711591

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Methylenetetrahydrofolate reductase in cultured human cells. I. Growtha and metabolic studies.

Authors:  D S Rosenblatt; R W Erbe
Journal:  Pediatr Res       Date:  1977-11       Impact factor: 3.756

2.  Methylenetetrahydrofolate reductase in cultured human cells. II. Genetic and biochemical studies of methylenetetrahydrofolate reductase deficiency.

Authors:  D S Rosenblatt; R W Erbe
Journal:  Pediatr Res       Date:  1977-11       Impact factor: 3.756

3.  Pathological findings in 5,10-methylene tetrahydrofolate reductase deficiency.

Authors:  D R Beckman; G Hoganson; S Berlow; E F Gilbert
Journal:  Birth Defects Orig Artic Ser       Date:  1987

4.  Fluorescent modification of adenosine-containing coenzymes. Biological activities and spectroscopic properties.

Authors:  J A Secrist; J R Barrio; N J Leonard; G Weber
Journal:  Biochemistry       Date:  1972-09-12       Impact factor: 3.162

5.  Central and peripheral nervous system pathology of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency.

Authors:  M Nishimura; K Yoshino; Y Tomita; S Takashima; J Tanaka; K Narisawa; I Kurobane
Journal:  Pediatr Neurol       Date:  1985 Nov-Dec       Impact factor: 3.372

6.  Demyelination and decreased S-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase deficiency.

Authors:  K Hyland; I Smith; T Bottiglieri; J Perry; U Wendel; P T Clayton; J V Leonard
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

7.  Infantile type of homocystinuria with N5,10-methylenetetrahydrofolate reductase defect.

Authors:  K Narisawa; Y Wada; T Saito; H Suzuki; M Kudo
Journal:  Tohoku J Exp Med       Date:  1977-02       Impact factor: 1.848

8.  Folate-responsive homocystinuria and "schizophrenia". A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity.

Authors:  J M Freeman; J D Finkelstein; S H Mudd
Journal:  N Engl J Med       Date:  1975-03-06       Impact factor: 91.245

9.  Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency.

Authors:  E Holme; B Kjellman; E Ronge
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

10.  Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease.

Authors:  S S Kang; P W Wong; A Susmano; J Sora; M Norusis; N Ruggie
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

View more
  5 in total

1.  Betaine dose and treatment intervals in therapy for homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency.

Authors:  N Sakura; H Ono; S Nomura; H Ueda; N Fujita
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

2.  Reversal of respiratory failure in both neonatal and late onset isolated remethylation disorders.

Authors:  A Broomfield; L Abulhoul; W Pitt; E Jameson; M Cleary
Journal:  JIMD Rep       Date:  2014-07-06

3.  Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid.

Authors:  Sarika U Peters; Lynne M Bird; Virginia Kimonis; Daniel G Glaze; Lina M Shinawi; Terry Jo Bichell; Rene Barbieri-Welge; Mark Nespeca; Irina Anselm; Susan Waisbren; Erica Sanborn; Qin Sun; William E O'Brien; Arthur L Beaudet; Carlos A Bacino
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

4.  An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria.

Authors:  Angela Matthews; Trevor N Johnson; Amin Rostami-Hodjegan; Anupam Chakrapani; J Edward Wraith; Stuart J Moat; James R Bonham; Geoffrey T Tucker
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

5.  Clinical pattern, mutations and in vitro residual activity in 33 patients with severe 5, 10 methylenetetrahydrofolate reductase (MTHFR) deficiency.

Authors:  Martina Huemer; Regina Mulder-Bleile; Patricie Burda; D Sean Froese; Terttu Suormala; Bruria Ben Zeev; Patrick F Chinnery; Carlo Dionisi-Vici; Dries Dobbelaere; Gülden Gökcay; Mübeccel Demirkol; Johannes Häberle; Alexander Lossos; Eugen Mengel; Andrew A Morris; Klary E Niezen-Koning; Barbara Plecko; Rossella Parini; Dariusz Rokicki; Manuel Schiff; Mareike Schimmel; Adrian C Sewell; Wolfgang Sperl; Ute Spiekerkoetter; Beat Steinmann; Grazia Taddeucci; Jose M Trejo-Gabriel-Galán; Friedrich Trefz; Megumi Tsuji; María Antònia Vilaseca; Jürgen-Christoph von Kleist-Retzow; Valerie Walker; Jiri Zeman; Matthias R Baumgartner; Brian Fowler
Journal:  J Inherit Metab Dis       Date:  2015-05-30       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.